Weekly short infusions of gemcitabine are not associated with suppression of lymphatic activity in patients with solid tumors.
Daikeler
T
T
Maas
K
K
Hartmann
J T
JT
Kanz
L
L
Bokemeyer
C
C
D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000627:therapeutic use / Q000633:toxicity; D016516:CD4-CD8 Ratio / Q000187:drug effects; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use / Q000633:toxicity; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D007694:Killer Cells, Natural / Q000187:drug effects; D008214:Lymphocytes / Q000187:drug effects*; D008297:Male; D009369:Neoplasms / Q000188:drug therapy*; D000093542:Gemcitabine
D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D000093542:Gemcitabine